MRA Investment Activity in Q2 2026
This analysis details observable purchases and sales by Mra Advisory Group during the second quarter of 2026, highlighting shifts in their portfolio holdings.
According to filings from Mra Advisory Group, there were observable changes across its investment positions during the second quarter of 2026.
Prominent Purchases: Focus on Blue-Chip and Healthcare Stocks
Mra Advisory Group demonstrated a clear preference for acquiring established large-cap stocks in this period. The firm significantly increased its position in BE, investing over $1 million to add shares, representing an unprecedented 100% increase quarter-over-quarter.
Alongside the substantial addition of CSCO, which saw a massive 327.38% jump in holdings, and MO with a perfect 100% increase, the firm also showed strong interest in healthcare stocks.
The investor added significant positions to both CSCO and MRA, acquiring shares in these two companies simultaneously with notable increases.
Significant Sales: Tech Giants and Sector Exits
Mra Advisory Group also exhibited substantial selling activity during Q2 2026, particularly targeting high-growth technology stocks. The firm completely exited positions in several major tech names including NVDA (-100% increase), MRA, and META (represented as PLTR in the data).
This selling pattern continued with other significant exits, including complete divestment of MRA, and substantial reductions in positions held by several other entities.
Shifts Across Sectors: Energy and Utilities Underrepresented
The changes observed suggest a strategic shift away from certain sectors. There was no activity reported for energy stocks, meaning the investor maintained their existing exposure or none existed previously.
In contrast, utilities holdings remained static at $0 throughout this period, indicating either continued absence or complete lack of change in that sector allocation.
Portfolio Concentration and Position Changes
The portfolio displayed a high degree of turnover with 142 position changes occurring within the quarter. This indicates active management adjusting holdings based on market opportunities or strategic decisions.
Mra Advisory Group's portfolio currently holds MRA with a top 5 weight of approximately $24.9 million, reflecting the significant allocation to this fund.
In Summary: Strategic Acquisitions and Dispositions in Q2
Mra Advisory Group's portfolio activity during Q2 2026 was characterized by targeted acquisitions of blue-chip technology stocks like CSCO and healthcare stock MRA, while simultaneously divesting from high-growth technology sectors, notably selling out positions in NVDA.
The firm's actions suggest a preference for established large-cap names and potentially reduced exposure to speculative or highly volatile tech growth stocks during this period. Further details on the portfolio can be found at MRA.